Enhancing Heart Failure Detection in the General Population Using the Steatosis‐Associated Fibrosis Estimator
Clinical Cardiology · 2026-04 · 49 (4)
DOI: 10.1002/clc.70318 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Cardiology, online erschienen am 20.04.2026. Verfasst von Wenrui Shi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Fuwai Shenzhen Hospital, Chinese Academy of Medical Sciences, Shenzhen, Guangdong Province, China. Hauptthemen laut MEDLINE: Heart Failure, Non-alcoholic Fatty Liver Disease, Liver Cirrhosis. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Purpose
Non‐alcoholic fatty liver disease and its fibrotic sequelae have been implicated in the development of cardiovascular complications. This study investigated the association between the steatosis‐associated fibrosis estimator (SAFE) and prevalent heart failure (HF), as well as evaluated whether SAFE could improve HF detection in the general population.
Methods
A total of 33,566 participants from the 2003–2018 National Health and Nutrition Examination Survey were included. HF was identified based on self‐reported medical history.
Results
The estimated HF prevalence was 3.00%. After adjusting for demographic, anthropometric, laboratory, and medical history factors, each one‐standard‐deviation increase in SAFE correlated with a 58.0% rise in HF risk. Individuals in the highest quartile of SAFE had a 2.777‐fold risk of HF compared to those in the lowest quartile. Smooth‐curve modeling revealed an almost linear association between SAFE and HF, and subgroup analyses supported this relationship across diverse populations. Incorporating SAFE into standard cardiovascular risk factors slightly improved HF discrimination (AUC: 0.873 vs. 0.876, p < 0.001). Reclassification metrics provided additional evidence for SAFE's incremental value.
Conclusion
This study identified a nearly linear and robust relationship between SAFE and prevalent HF, suggesting that SAFE may serve as a useful indicator for enhancing HF detection in the general population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Fuwai Shenzhen Hospital, Chinese Academy of Medical Sciences, Shenzhen, Guangdong Province, China.
- Department of Cardiology, Shanghai Chest Hospital, Affiliated to Shanghai Jiao Tong University, Shanghai, China.
- School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Department of Cardiology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong Province, China.
ORCID-Profile: Wenrui Shi, Yuancong Wu
Zitieren
APA
Shi, W., Shi, Y., Park, J., & Wu, Y. (2026). Enhancing Heart Failure Detection in the General Population Using the Steatosis‐Associated Fibrosis Estimator. Clinical Cardiology, 49(4). https://doi.org/10.1002/clc.70318
Vancouver
Shi W, Shi Y, Park J, Wu Y. Enhancing Heart Failure Detection in the General Population Using the Steatosis‐Associated Fibrosis Estimator. Clinical Cardiology. 2026;49(4). doi:10.1002/clc.70318
BibTeX
@article{Shi2026,
author = {Shi, Wenrui and Shi, Yangbin and Park, Jieun and Wu, Yuancong},
title = {Enhancing Heart Failure Detection in the General Population Using the Steatosis‐Associated Fibrosis Estimator},
journal = {Clinical Cardiology},
year = {2026},
volume = {49},
number = {4},
doi = {10.1002/clc.70318}
}
EUVIMED